Adaptive Biotechnologies Corporation
A maker of tools that read the immune system's genetic code. Its FDA-authorized clonoSEQ test hunts for the tiny traces of cancer cells that can linger after treatment for blood cancers like multiple myeloma, helping doctors spot a possible relapse early. The company was founded in 2009 by brothers Harlan and Chad Robins, after Harlan's lab work at a Seattle research center cracked how to sequence T-cell receptors; Chad, a business guy who joked he couldn't tell a T-cell receptor from a T-bone steak, handled the company side.
Bought 250.0K · Sold 7.41M
Sold 7.41M
Sold 1.00M
Sold 2.81M
Granted 100.0K · Sold 345.0K
Granted 4.06M · Sold 3.64M
Bought 250.0K
Granted 2.93M · Sold 1.60M
Granted 790.0K · Sold 258.4K
Granted 424.0K · Sold 136.4K
Granted 2.88M · Sold 2.50M
Granted 1.50M · Sold 1.27M
Granted 469.7K · Sold 215.8K
Granted 679.4K · Bought 2.5K · Sold 428.5K
Granted 250.3K · Sold 10.0K
Granted 296.1K · Sold 81.3K
Granted 248.0K · Sold 72.6K
Granted 302.5K · Sold 164.4K
Granted 88.3K
Granted 164.7K · Sold 95.0K
Granted 187.3K · Sold 125.0K
Granted 223.0K · Bought 11.2K · Sold 223.0K
Granted 29.1K
Granted 25.9K
Granted 23.0K
Granted 965.0K · Bought 1.0K · Sold 944.4K
Granted 183.6K · Sold 166.5K
Granted 258.4K · Sold 242.7K
Granted 29.8K · Sold 20.6K
Granted 66.5K · Sold 65.0K
Granted 1.5K
Granted 140.0K · Sold 140.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Halvorsen Ole Andreas +6 co-filers10% owner · 7 transactions | — | 30.99Mas of Nov 2020 | — | 250.0K | 7.41M |
| Halvorsen Ole Andreas +7 co-filers10% owner · 2 transactions | — | 30.99Mas of Nov 2020 | — | — | 7.41M |
| Halvorsen Ole Andreas +8 co-filers10% owner · 1 transaction | — | 29.99Mas of Dec 2020 | — | — | 1.00M |
| Goel David E. +1 co-filerReporting owner · 15 transactions | — | 12.34Mas of Mar 2021 | — | — | 2.81M |
| Zoltners Andris ADirector · 7 transactions | — | 3.62Mas of Jan 2020 | 100.0K | — | 345.0K |
| Robins Chad MCEO and Chairman, Director · 214 transactions | — | 2.18M | 4.06M | — | 3.64M |
| Halvorsen Ole Andreas +6 co-filers10% owner · 5 transactions | — | 1.68Mas of Jul 2019 | — | 250.0K | — |
| Robins Harlan SChief Scientific Officer · 223 transactions | — | 1.41M | 2.93M | — | 1.60M |
| Peterson TychoChief Financial Officer · 11 transactions | — | 531.6Kas of Mar 2024 | 790.0K | — | 258.4K |
| Bobulsky SusanChief Commercial Officer, MRD · 17 transactions | — | 406.8K | 424.0K | — | 136.4K |
| Rubinstein JuliePresident and COO · 318 transactions | — | 396.8K | 2.88M | — | 2.50M |
| Benzeno SharonChief Commercial Ofc Imm Med · 123 transactions | — | 299.5K | 1.50M | — | 1.27M |
| Piskel KyleChief Financial Officer · 30 transactions | — | 256.7K | 469.7K | — | 215.8K |
| Lo FrancisChief People Officer · 70 transactions | — | 253.4K | 679.4K | 2.5K | 428.5K |
| Neupert Peter MDirector · 10 transactions | — | 240.3K | 250.3K | — | 10.0K |
| Sood NitinChief Commercial Officer, MRD · 9 transactions | — | 214.8Kas of Aug 2023 | 296.1K | — | 81.3K |
| Adams R MarkChief Operating Officer · 25 transactions | — | 175.4Kas of Apr 2023 | 248.0K | — | 72.6K |
| Taylor Stacy LSVP and General Counsel · 83 transactions | — | 139.4Kas of Aug 2024 | 302.5K | — | 164.4K |
| Owen Katey EinterzDirector · 6 transactions | — | 88.3K | 88.3K | — | — |
| Pellini Michael JDirector · 12 transactions | — | 69.7Kas of Mar 2025 | 164.7K | — | 95.0K |
| Hershberg RobertDirector · 43 transactions | — | 62.3K | 187.3K | — | 125.0K |
| Hill Nancy LouiseEVP, Operations & Program Mana · 24 transactions | — | 36.2Kas of Jan 2021 | 223.0K | 11.2K | 223.0K |
| Thorsen HenningSVP, Commercial Operations · 1 transaction | — | 29.1Kas of May 2021 | 29.1K | — | — |
| Trigg LeslieDirector · 3 transactions | — | 25.9Kas of Mar 2023 | 25.9K | — | — |
| Conroy Kevin TDirector · 3 transactions | — | 23.0Kas of Mar 2023 | 23.0K | — | — |
| Cohen Chad MChief Financial Officer · 132 transactions | — | 21.6Kas of Dec 2021 | 965.0K | 1.0K | 944.4K |
| Baldo LanceChief Medical Officer · 40 transactions | — | 17.2Kas of Mar 2022 | 183.6K | — | 166.5K |
| Griffin Michelle ReneeDirector · 46 transactions | — | 15.6K | 258.4K | — | 242.7K |
| Palaniappan JyotiSVP, Diagnostics, T-Detect · 15 transactions | — | 9.8Kas of Jul 2021 | 29.8K | — | 20.6K |
| Dobmeier EricDirector · 23 transactions | — | 1.5Kas of Feb 2021 | 66.5K | — | 65.0K |
| Goel David E.Director · 1 transaction | — | 1.5Kas of Feb 2021 | 1.5K | — | — |
| Sang CharlesSVP, External Affairs · 9 transactions | — | 0as of Dec 2020 | 140.0K | — | 140.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -30.86M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.